By Donna Loyle, communications specialist, LIMR
The Main Line Health Center for Clinical Cancer Research was awarded a Silver Certificate of Excellence from the National Cancer Institute (NCI) for exceptional achievement in patient enrollments in the NCI Community Oncology Research Program (NCORP). This is the second consecutive year the team has received this prestigious honor. Since 2014, the team has enrolled 344 patients: 178 in cancer control trials and 166 in cancer treatment trials.
Because Main Line Health is one of only 34 NCORP community sites in the United States, our patients have access to state-of-the-art clinical trials and new cancer treatments before they become available to the general public. MLH NCORP is led by principal investigator Albert DeNittis, MD, Chief of Radiation Oncology at Lankenau Medical Center.
“We are proud to once again receive a Silver Certificate from NCI for our impressive ongoing record of patient enrollments in NCORP,” said Dr. DeNittis. “Research plays a vital role in patient outcomes. Based on research findings, we are able to offer patients at Main Line Health the latest treatment options for their particular cancers, including promising immunotherapies. Our involvement in the program also means that our cancer patients can play a more active role in their health care.”
Currently, Main Line Health is participating in more than 40 cancer clinical trials. For more on the Center for Clinical Cancer Research and to search for available cancer trials for your patients, visit https://bit.ly/2P74GSZ